Pyridyl substituted indole compounds

Patent metadata

Field	Value
Publication number	US-10660877-B2
Application number	US-201716330964-A
Country	US
Kind code	B2
Filing date	Sep 8, 2017
Priority date	Sep 9, 2016
Publication date	May 26, 2020
Grant date	May 26, 2020

Abstract

Disclosed are compounds of Formula (I) N-oxide, or salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

First claim

What is claimed is:

1. A compound of Formula (I)

N-oxide, or salt thereof, wherein:
R 1 is H, Cl, —CN, C 1-4 alkyl, C 1-3 fluoroalkyl, C 1-3 hydroxy-fluoroalkyl, —CR z ═CH 2 , C 3-6 cycloalkyl, —CH 2 (C 3-6 cycloalkyl), —C(O)O(C 1-3 alkyl), or tetrahydropyranyl;
each R 2 is independently halo, —CN, —OH, —NO 2 + , C 1-3 alkyl, C 1-2 fluoroalkyl, C 1-3 hydroxyalkyl, C 1-3 aminoalkyl, —(CH 2 ) 0-4 O(C 1-3 alkyl), C 1-3 fluoroalkoxy, C 2-4 alkoxyalkoxy, —O(CH 2 ) 1-2 NR x R x , —C(O)O(C 1-3 alkyl), —C(O)NR y R y , —NR y R y , —NR x C(O)(C 1-3 alkyl), —NR x (CH 2 -cyclopropyl), C 3-6 cycloalkyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, triazolyl, or —C(O)(thiazolyl);
R 3 is:
(a) -L 1 -A; or
(b) H, C 1-6 alkyl, C 1-3 fluoroalkyl, C 1-3 cyanoalkyl, C 1-6 hydroxyalkyl, C 1-3 hydroxy-fluoroalkyl, —CR x R x CR x (OH)CR x ═CR x R x , —(CR x R x ) 1-4 O(C 1-3 alkyl), —(CR x R x ) 1-4 O(CR x R x ) 1-3 O(C 1-3 alkyl), —CR x R x CR x (OH)CH 2 O(C 1-3 alkyl), —(CR x R x ) 1-3 S(C 1-3 alkyl), —(CH 2 ) 1-3 C(O)OC(CH 3 ) 3 , —(CR x R x ) 0-3 NR x R y , —(CR x R x ) 0-3 NR x (C 1-4 hydroxyalkyl), —CR x R x CR x (OH)CH 2 NR x R y , —C(O)H, —C(O)(C 1-6 alkyl), —C(O)(C 1-3 hydroxyalkyl), —C(O)(C 1-3 fluoroalkyl), —C(O)(C 1-3 chloroalkyl), —C(O)(C 1-3 cyanoalkyl), —(CR x R x ) 0-3 C(O)OH, —C(O)(CH 2 ) 0-2 O(C 1-4 alkyl), —C(O)(CR x R x ) 0-2 O(CR x R x ) 1-2 O(C 1-3 alkyl), —C(O)CR x R x S(O) 2 (C 1-3 alkyl), —C(O)CR x R x NR x S(O) 2 (C 1-3 alkyl), —C(O)CR x R x OC(O)(C 1-3 alkyl), —C(O)(CR x R x ) 0-3 NR y R y , —C(O)(CR x R x ) 0-1 NR x (C 1-3 cyanoalkyl), —C(O)(CR x R x ) 0-2 NR y (C 1-6 hydroxyalkyl), —C(O)(CR x R x ) 0-1 NR x (C 1-3 fluoroalkyl), —C(O)(CR x R x ) 0-1 NR x (C 1-5 hydroxy-fluoroalkyl), —C(O)(CR x R x ) 0-1 NR x (CH 2 ) 1-2 O(C 1-3 hydroxyalkyl), —C(O)(CR x R x ) 0-1 NR x (CH 2 ) 1-2 NR x C(O)(C 1-2 alkyl), —C(O)(CR x R x ) 0-1 NR x ((CR x R x ) 1-2 O(C 1- 2 alkyl)), —C(O)CR x (NH 2 )(CR x R x ) 1-4 NR x R x , —C(O)CR x (NH 2 )(CR x R x ) 1-4 NR x C(O)NR x R x , —C(O)(CR x R x ) 0-3 NR x (CH 2 ) 0-1 C(O)(C 1-3 alkyl), —C(O)(CR x R x ) 0-1 NR x (CH 2 ) 0-1 C(O)(C 1-3 cyanoalkyl), —C(O)(CR x R x ) 0-1 NR x (CH 2 ) 1-2 C(O)NR y R y , —C(O)(CR x R x ) 1-3 C(O)NR y R y , —C(O)(CR x R x ) 0-1 NR x (CHR y (CH 2 OH)), —(CR x R x ) 1-2 C(O)NR y R y , —(CR x R x ) 1-2 C(O)NR y (C 1- 3 fluoroalkyl), —(CR x R x ) 1-2 C(O)NR y (C 1-4 hydroxyalkyl), —(CR x R x ) 1-2 C(O)NR y (C 1-3 cyanoalkyl), —(CR x R x ) 1-2 C(O)NR x (CH 2 ) 1-2 O(C 1-3 alkyl), —(CR x R x ) 1-2 C(O)NR x CH(C 1-4 alkyl)(C 1-3 hydroxyalkyl), —(CH 2 ) 1-2 C(O)NR x (CH 2 ) 1-2 C(O)NR x R x , —(CH 2 ) 1-2 C(O)NR x (CH 2 ) 1-2 S(O) 2 OH, —(CH 2 ) 1-2 C(O)NR x (CH 2 ) 1-2NR x C(O)(C 1-3 alkyl), —(CH 2 ) 1-2 C(O)NR x (CH 2 ) 1-3 NR x R x , —(CH 2 ) 1-2 C(O)N(CH 2 CH 3 )(CH 2 ) 1-3 NR x R x , —(CH 2 ) 0-2 S(O) 2 (C 1-4 alkyl), —(CH 2 ) 0-2 S(O) 2 (C 1-3 fluoroalkyl), —(CH 2 ) 0-2 S(O) 2 NR x R x , —C(O)C(O)OH, —C(O)C(O)NR y R y , or —C(O)C(O)NR y (CR x R x ) 1-2 NR y R y ;

L 1 is a bond, —(CR x R x ) 1-2 —, —(CR x R x ) 1-2 CR x (OH)—, —(CR x R x ) 1-2 O—, —CR x R x C(O)—, —(CR x R x ) 2 NR x (CR x R x ) 0-1 —, —CR x R x C(O)NR x (CR x R x ) 0-4 —, —C(O)(CR x R x ) 0-3 —, —C(O)(CR x R x ) 0-2 NR x (CR x R x ) 0-2 —, —C(O)(CR x R x ) 0-2 N(C 1-2 hydroxyalkyl)(CR x R x ) 0-2 —, —C(O)(CR x R x ) 0-2 NR x (CR x R x ) 1-2 CR x (OH)—, —C(O)(CR x R x ) 1-2 C(O)NR x —, —(CR x R x ) 0-2 C(O)NR x (CR x R x ) 1-2 CR x (OH)—, —(CR x R x ) 0-2 C(O)N(C 1-2 hydroxyalkyl)(CR x R x ) 1-2 —, —C(O)(CR x R x ) 0-1 O—, —C(O)(CR x R x ) 1-2 NHS(O) 2 —, —C(O)CR x (NH 2 )CR x R x —, —C(O)C(O)(CR x R x ) 0-2 —, —C(O)C(O)NR x (CR x R x ) 0-2 —, —C(O)NR x (CR x R x ) 1-2 —, or —S(O) 2 —;
A is 2-oxa-6-azaspiro[3,3]heptanyl, 4-oxaspiro[2.5]octanyl, 7-azaspiro[3.5]nonanyl, 8-azabicyclo[3.2.1]octanyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 9-azabicyclo[3.3.1]nonanyl, adamantanyl, azepanyl, azetidinyl, C 3-6 cycloalkyl, diazepanyl, dihydroinonyl, dihydropyrimidinonyl, dioxidoisothiazolidinyl, dioxidothiazinanyl, dioxotetrahydrothiophenyl, dioxotetrahydrothiopyranyl, dioxothiomorpholinyl, furanyl, imidazolyl, imidazolidinonyl, indolyl, isoquinolinyl, isoxazolyl, morpholinyl, morpholinonyl, naphthalenyl, octahydrocyclopenta[b]pyranyl, oxazolidinonyl, oxadiazolyl, oxetanyl, oxazolyl, phenyl, piperidinyl, piperidinonyl, piperazinyl, piperazinonyl, pyrazinyl, pyrazolyl, pyridazinonyl, pyridinonyl, pyridinyl, pyrimidinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolyl, quinolinyl, quinolizinonyl, tetrahydrofuranyl, tetrahydropyranyl, tetrazolyl, thiadiazolyl, thiazolyl, or triazolyl, each substituted with -L 2 -R a and zero to 4 R b ;
L 2 is a bond or —CR x R x —;
R a is:
(a) H, F, C 1 , —CN, —OH, C 1-6 alkyl, C 1-3 fluoroalkyl, C 1-5 hydroxyalkyl, —(CH 2 ) 0-4 O(C 1-3 alkyl), —(CR x R x ) 1-3 S(C 1-3 alkyl), —(CR x R x ) 1-3 NHC(O)O(C 1-4 alkyl), —(CR x R x ) 1-3 NR y R y , —(CR x R x ) 1-3 C(O)NR y R y , —O(C 1-3 fluoroalkyl), —S(O) 2 NR x R x , —O(CR x R x ) 1-3 NR x R x , —NHS(O) 2 (C 1-3 alkyl), —NR x R x , —NR x (C 1-4 alkyl), —NR x C(O)(C 1-4 alkyl), —(CR x R x ) 0-3 C(O)OH, —C(O)(C 1-5 alkyl), —C(O)(C 1-3 fluoroalkyl), —C(O)O(C 1-4 alkyl), —C(O)NH(C 1-3 cyanoalkyl), —C(O)NR y R y , —C(O)NR x CH 2 C(O)NR x R x , or —C(O)NR x CH 2 CH 2 NHC(O)(C 1-3 alkyl);
(b) C 3-6 cycloalkyl or —C(O)NH(C 3-6 cycloalkyl), wherein each cycloalkyl is substituted with zero to 2 substituents independently selected from —OH, C 1-3 alkyl, C 1-3 hydroxyalkyl, C 1-3 fluoroalkyl, and —C(O)O(C 1-3 alkyl); or
(c) A 1 , —CH 2 A 1 , —C(O)A 1 , —NR x A 1 , or —C(O)NR x A 1 , wherein A 1 is furanyl, imidazolyl, indolyl, isoxazolyl, morpholinyl, octahydropyrrolo[3,4-c]pyrrolyl, oxazolyl, oxetanyl, phenyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, thiadiazolyl, thiazolyl, thiophenyl, or triazolyl, each substituted with zero to three substituents independently selected from —OH, C 1-3 alkyl, C 1-3 hydroxyalkyl, —C(O)(C 1-2 alkyl), —C(O)O(C 1-3 alkyl), —NR x R x , phenyl, trifluoromethyl-phenyl, —CH 2 (bromophenyl), and —CH 2 CH 2 (pyrrolidinyl);

each R 4 is independently F, —OH, C 1-2 alkyl, or —OCH 3 ; or two R 4 attached to the same carbon atom form ═O;
each R 5 is independently F, C 1 , —CN, C 1-2 alkyl, C 1-2 fluoroalkyl, or —OCH 3 ;
each R b is independently F, —CH 3 , —CF 3 , or —OCH 3 ;
each R x is independently H or —CH 3 ;
each R y is independently H or C 1-6 alkyl;
R z is H, C 1-2 alkyl, or C 1-2 fluoroalkyl;
m is zero, 1, 2, 3, or 4;
n is zero, 1, or 2; and
p is zero, 1, 2, 3, or 4.

2. The compound according to claim 1 , N-oxide, or salt thereof, wherein:
R 1 is H, Cl, —CN, C 1-4 alkyl, C 1-3 fluoroalkyl, C 1-3 hydroxy-fluoroalkyl, —CR z ═CH 2 , C 3-6 cycloalkyl, —CH 2 (C 3-6 cycloalkyl), —C(O)O(C 1-3 alkyl), or tetrahydropyranyl;
each R 2 is independently halo, —CN, —OH, —NO 2 , C 1-3 alkyl, C 1-2 fluoroalkyl, C 1-3 hydroxyalkyl, C 1-3 aminoalkyl, —(CH 2 ) 0-4 O(C 1-3 alkyl), C 1-3 fluoroalkoxy, C 2-4 alkoxyalkoxy, —O(CH 2 ) 1-2 NR x R x , —C(O)O(C 1-3 alkyl), —C(O)NR y R y , —NR y R y , —NR x C(O)(C 1-3 alkyl), —NR x (CH 2 -cyclopropyl), C 3-6 cycloalkyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, triazolyl, or —C(O)(thiazolyl);
R 3 is:
(a) -L 1 -A; or
(b) H, C 1-6 alkyl, C 1-3 fluoroalkyl, C 1-3 cyanoalkyl, C 1-6 hydroxyalkyl, C 1-3 hydroxy-fluoroalkyl, —CR x R x CR x (OH)CR x ═CR x R x , —(CR x R x ) 1-4 O(C 1-3 alkyl), —(CR x R x ) 1-4 O(CR x R x ) 1-3 O(C 1-3 alkyl), —CH 2 CH(OH)CH

Assignees

• Bristol Myers Squibb Co

Inventors

• Dyckman Alaric J
• Dodd Dharmpal S
• Haque Tasir Shamsul
• Lombardo Louis J
• Macor John E
• Mussari Christopher P
• Pasunoori Laxman
• Poss Michael A
• Kumar Sreekantha Ratna
• Posy Shoshana L
• Tortolani David R
• Whiteley Brian K
• Sistla Ramesh Kumar
• Hegde Subramanya
• Ramachandra Reddy Anupama Kandhi

Classifications

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61K31/404 Primary

  Indoles, e.g. pindolol · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title